Bowel Perforation in a Patient with Hepatocellular Carcinoma during Lenvatinib Treatment

zu Verbundenen Objekten

We present a case of severe bowel perforation during lenvatinib treatment for advanced hepatocellular carcinoma. Although the Hartmann’s procedure was performed, the patient died 48 h after the operation. The histopathological findings suggested that lenvatinib was involved in the etiology of bowel perforation in this case.

Standort
Deutsche Nationalbibliothek Frankfurt am Main
Umfang
Online-Ressource
Sprache
Englisch

Erschienen in
Bowel Perforation in a Patient with Hepatocellular Carcinoma during Lenvatinib Treatment ; volume:16 ; number:2 ; year:2022 ; pages:502-506 ; extent:5
Case reports in gastroenterology ; 16, Heft 2 (2022), 502-506 (gesamt 5)

Urheber
Mizokami, Ken
Watanabe, Akiko
Yamaguchi, Eriko
Saito, Akira

DOI
10.1159/000525569
URN
urn:nbn:de:101:1-2022092200560520011552
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:38 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Mizokami, Ken
  • Watanabe, Akiko
  • Yamaguchi, Eriko
  • Saito, Akira

Ähnliche Objekte (12)

Perforation of the Small Intestine after Introduction of Lenvatinib in a Patient with Advanced Hepatocellular Carcinoma

Perforation of the Small Intestine after Introduction of Lenvatinib in a Patient with Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma Showing Pathological Complete Response to Lenvatinib Monotherapy

Hepatocellular Carcinoma Showing Pathological Complete Response to Lenvatinib Monotherapy

Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma

Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma

Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma

Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma

Progressive erythrocytosis under lenvatinib treatment in patients with advanced hepatocellular carcinoma

Progressive erythrocytosis under lenvatinib treatment in patients with advanced hepatocellular carcinoma

Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study

Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study

Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience

Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience

Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma

Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma

Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib

Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib

Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma

Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma

Lenvatinib Might Induce Activation of Host Immunity in Patients with Hepatocellular Carcinoma

Lenvatinib Might Induce Activation of Host Immunity in Patients with Hepatocellular Carcinoma

Pathological Complete Response in Conversion Hepatectomy Induced by Lenvatinib for Advanced Hepatocellular Carcinoma

Pathological Complete Response in Conversion Hepatectomy Induced by Lenvatinib for Advanced Hepatocellular Carcinoma

Verbundene Objekte